Last reviewed · How we verify
TachoSil® patches
TachoSil patches work by promoting hemostasis and tissue sealing through the release of fibrinogen and thrombin.
TachoSil patches work by promoting hemostasis and tissue sealing through the release of fibrinogen and thrombin. Used for Hemostasis and tissue sealing in surgical procedures.
At a glance
| Generic name | TachoSil® patches |
|---|---|
| Sponsor | Swiss Cancer Institute |
| Drug class | Hemostatic agent |
| Modality | Small molecule |
| Therapeutic area | Surgery |
| Phase | Phase 3 |
Mechanism of action
TachoSil patches contain a combination of human fibrinogen and human thrombin that are released when the patch comes into contact with blood. This release of fibrinogen and thrombin triggers the coagulation cascade, leading to the formation of a fibrin clot that seals the wound and promotes hemostasis.
Approved indications
- Hemostasis and tissue sealing in surgical procedures
Common side effects
- Hypersensitivity reactions
Key clinical trials
- A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery (PHASE1, PHASE2)
- Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial (PHASE4)
- Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation (NA)
- Tachosil for the Prevention of Symptomatic Lymph Cysts (PHASE3)
- Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer (PHASE3)
- Application of Tachosil During Lymphadenectomy (PHASE4)
- The Effect of Application of TachoSil® in Pancreatoduodenectomy (PHASE4)
- Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TachoSil® patches CI brief — competitive landscape report
- TachoSil® patches updates RSS · CI watch RSS
- Swiss Cancer Institute portfolio CI